Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

RPR/INGN-201 + radiotherapy provides supraadditive effects in prostate cancer xenograft models

Nov. 17, 1999

Lorus files IND seeking clearance for phase I/II clinical trials of GTI-2040

Nov. 17, 1999

Foscan receives orphan drug designation in U.S.; MAA accepted in E.U.

Nov. 17, 1999

Pharmaceutical agents useful as vitronectin antagonists and methods of use

Nov. 17, 1999

Kinase inhibitors developed at Boehringer Ingelheim as potential anticancer agents

Nov. 17, 1999

Ontogen completes phase I multidose oral study of MDR compound

Nov. 17, 1999

Preclinical data highlight Xcytrin's anticancer activity and novel mechanism of action

Nov. 17, 1999

New data reported on thalidomide for several cancer indications

Nov. 17, 1999

OHSU study will evaluate vitamin D in patients with recurring prostate cancer

Nov. 16, 1999

Kotobuki presents new sulfonamide MMP inhibitors

Nov. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...